close

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs, known as pharmacological chaperones, for the treatment of various human genetic diseases. Pharmacological chaperones selectively bind to the target protein, increase the stability of the protein, help it fold into the three-dimensional shape, and allow proper trafficking of the protein, thereby increasing protein activity, enhance cellular function, and reduce cell stress. It is primarily targeting lysosomal storage disorders, which are severe, chronic genetic diseases. The company's products include Amigal, which has completed Phase II clinical trial for the treatment of Fabry disease; Plicera, a Phase II clinical trial product for the treatment of Gaucher disease; and AT2220, a Phase II clinical trial product for the treatment of Pompe disease. Amicus Therapeutics has a strategic collaboration with Shire Pharmaceuticals Ireland Ltd. to jointly develop three lead pharmacological chaperone compounds for lysosomal storage disorders. The company was founded in 2002 and is based in Cranbury, New Jersey.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	5.77
Volume	196067
Volume Avg	160111
52 Week High	8.12
52 Week Low	2.10
PE	N/A
PE (group average)	N/A
EPS Year	-1.29
EPS change Q/Q	-18.75%
EPS change Q/Q Yr ago	-27.78%
EPS change Q/Q next Q est	-34.48%
EPS change Y/Y	-85.33%
REV change Q/Q	566.67%
REV change Q/Q Yr ago	-100%
EPS next Q est	-0.29
EPS next Y est	-1.01
Divident Annual	0.00
Dividend Yield	0%